UNSPSC 51332503: Azaperone

This classification denotes an antipsychotic agent with the molecular formula C19H22FN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19BV78AK7W, chemically known as 1-butanone, 1-(4-fluorophenyl)-4-(4-(2-pyridinyl)-1-piperazinyl)- but generally known as azaperone, which bears US NIH Compound Identifier 15443. Azaperone most often comes in base and dimaleate forms. European Medicines Agency schedules Azaperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05636MIG.

UNSPSC 51332503 Azaperone is a Commodity code that in practice captures state and local procurement of pharmaceutical products, naloxone rescue medications, and drug deactivation systems for public health and emergency response. The recent solicitation activity under this code shows state and local governments buying naloxone units paired with drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and exploring direct-to-manufacturer prescription fulfillment models to improve cost management and supply chain efficiency. The issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administered by the Minnesota Department of Administration). The code shows activity across both direct county procurement and broader state-level cooperative purchasing vehicles that serve multiple participating jurisdictions.

Geographic activity concentrates in Florida, Texas, and Minnesota, with MMCAP's cooperative agreement extending to Oregon and other participating states. Representative recent opportunities include Seminole County's IFB60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries beginning July 2026, awarded on a fixed-fee basis with a two-year initial term and one-year renewal option; MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, targeting July 1, 2026 contract effectiveness and evaluating vendors primarily on price competitiveness (75 percent weight); and the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs before issuing a formal competitive procurement. Vendors responding to these opportunities must hold FDA compliance certifications, Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, appropriate insurance coverage including commercial general liability and professional liability, and E-Verify authorization to work in the United States.